Last updated on November 2019

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type.


Brief description of study

Evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer's type.

 

Clinical Study Identifier: TX229956

Find a site near you

Start Over

Northwest Clinical Research Center

1951 152nd Pl NE Suite 200 Bellevue, WA United States
  Connect »